Business, energy, technology, markets and global industry news from Business News Today

non-small cell lung cancer

PharmaDeviceNews non-small cell lung cancer
Pharma & Biotech

Can Akeso’s ivonescimab ASCO plenary data reset expectations in lung cancer?

Akeso’s ivonescimab faces a defining ASCO test as lung cancer rivals watch whether PD-1/VEGF bispecifics can scale globally.

Read More
Representative image: Scientists review antibody-drug conjugate research in an oncology laboratory as Gilead Sciences’ Tubulis acquisition sharpens focus on next-generation ADC platforms, solid tumour pipelines and cancer drug development strategy.
Pharma & Biotech

Why Gilead’s $5bn Tubulis deal could reshape its solid tumour pipeline strategy

Gilead’s Tubulis deal strengthens its ADC pipeline, but oncology execution, safety and clinical proof now decide the upside.

Read More
Representative image: Clinicians reviewing lung cancer imaging and genomic test results, reflecting Bayer’s HYRNUO FDA Priority Review and the growing role of precision oncology in HER2-mutated non-small cell lung cancer treatment.
Pharma & Biotech

Why Bayer’s HYRNUO first-line FDA review could reshape HER2-mutated NSCLC treatment sequencing

Bayer has FDA momentum in HER2-mutated lung cancer. The harder test is whether HYRNUO can move earlier without stronger survival data.

Read More
Pharma & Biotech

Can Thermo Fisher help Nuvation Bio scale Ibtrozi supply for ROS1-positive NSCLC?

Rare cancer drugs need more than FDA approval. Nuvation Bio’s Ibtrozi test now shifts to U.S. supply reliability and launch execution.

Read More
Representative image: Advanced lung cancer research and oncology treatment planning are becoming central to the debate over whether Kelun-Biotech’s sacituzumab tirumotecan and pembrolizumab combination can reshape first-line NSCLC care.
Pharma & Biotech

Why Kelun-Biotech’s sac-TMT review could reshape China’s lung cancer ADC market

ADC ambition meets Keytruda dominance. Kelun-Biotech’s sac-TMT filing could test how far TROP2 combinations can move in lung cancer.

Read More
Representative image of an oncology consultation involving lung scan review, reflecting how Xcovery Holdings’ Ensacove launch and EVERSANA’s commercialization support could influence patient access in ALK-positive non-small cell lung cancer care.
Pharma & Biotech

Can EVERSANA help Xcovery turn Ensacove into a serious ALK-positive lung cancer contender?

ALK lung cancer has strong therapies already. Xcovery’s Ensacove now faces the harder test of access, adoption, and differentiation.

Read More
Pharma & Biotech

Why the first patient dosed in CatalYm’s VINCIT trial matters more than it seems.

CatalYm has dosed the first patient in its visugromab Phase 2/3 cachexia trial. Read why this oncology move could matter far beyond weight gain.

Read More
Pharma & Biotech

From lorlatinib to PF-08634404, how Pfizer is trying to reshape its oncology story at ASCO 2026

Pfizer’s ASCO 2026 oncology data span lorlatinib, talazoparib, tucatinib and new pipeline assets. Read what the updates could change next.

Read More
Pharma & Biotech

STK-012 shows promise in resistant lung cancer biology, but can Synthekine deliver in Phase 2?

Synthekine’s STK-012 showed encouraging AACR 2026 data in resistant NSCLC. Read what the results could mean for frontline lung cancer treatment.

Read More
Pharma & Biotech

Why Lantern Pharma’s LP-300 data in EGFR L858R NSCLC could reshape the post-osimertinib debate

Lantern Pharma’s LP-300 showed an early EGFR L858R lung cancer signal. Read what the FDA meeting and trial redesign could change next.

Read More